Literature DB >> 20349074

Modified concept for radioisotope-guided sentinel lymph node dissection in prostate cancer.

David Schilling1, Ulf Boekeler, Georgios Gakis, Christian Schwentner, Stefan Corvin, Karl Sotlar, Arndt-Christian Müller, Roland Bares, Arnulf Stenzl.   

Abstract

PURPOSE: To present a modified concept for sentinel lymph node (SLN)-guided pelvic lymph node dissection in prostate cancer.
METHODS: A total of 463 patients with histologically proven prostate cancer underwent SLN-guided lymph node dissection. The day before surgery patients received intraprostatic injection of Tc-99 m-labeled nanocolloid (Tc-NC) under transrectal ultrasound guidance. At the time of surgery, the lymph nodes of the obturator fossa were dissected routinely in all patients. After meticulous testing with a handheld gamma probe, all lymphatic tissues in predefined anatomic regions (external iliac, internal iliac, common iliacal and presacral) with Tc-NC uptake were additionally resected.
RESULTS: In 146 (12.8%) patients, SLN were located exclusively in the obturator fossa, but 317 patients (87.2%) underwent resection of additional sentinel regions. In 28 (6.1%) patients, 62 lymph node metastases were detected, and 32 (51.6%) of these were located outside the obturator fossa. Eight (28.6%) patients displayed lymph node metastases exclusively outside the obturator fossa and had been resected only because of positive SLN probing.
CONCLUSIONS: The obturator fossa comprises the major landing site of lymph node metastases, but more than half of the metastases are located outside this anatomic region. Routine resection of the obturator fossa with additional resection of positive sentinel regions improves staging accuracy compared to resection of the obturator fossa only.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20349074     DOI: 10.1007/s00345-010-0533-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  20 in total

1.  Detection rate and operating time required for gamma probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging.

Authors:  Sebastian H Warncke; Agostino Mattei; Frank G Fuechsel; Sebastian Z'Brun; Thomas Krause; Urs E Studer
Journal:  Eur Urol       Date:  2007-01-22       Impact factor: 20.096

2.  Laparoscopic sentinel lymph node dissection--a novel technique for the staging of prostate cancer.

Authors:  Stefan Corvin; David Schilling; Kai Eichhorn; Ilse Hundt; Joerg Hennenlotter; Aristotelis G Anastasiadis; Markus Kuczyk; Roland Bares; Arnulf Stenzl
Journal:  Eur Urol       Date:  2005-12-09       Impact factor: 20.096

3.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients.

Authors:  Gerald W Hull; Farhang Rabbani; Farhat Abbas; Thomas M Wheeler; Michael W Kattan; Peter T Scardino
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

4.  The sentinel lymph node concept in prostate cancer - first results of gamma probe-guided sentinel lymph node identification.

Authors:  F Wawroschek; H Vogt; D Weckermann; T Wagner; R Harzmann
Journal:  Eur Urol       Date:  1999-12       Impact factor: 20.096

5.  Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer.

Authors:  Alberto Briganti; Felix K-H Chun; Andrea Salonia; Nazareno Suardi; Andrea Gallina; Luigi Filippo Da Pozzo; Marco Roscigno; Giuseppe Zanni; Luc Valiquette; Patrizio Rigatti; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2006-08-31       Impact factor: 20.096

6.  Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.

Authors:  Dorothea Weckermann; Robert Dorn; M Trefz; Theodor Wagner; Friedhelm Wawroschek; Rolf Harzmann
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

7.  Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques.

Authors:  N N Stone; R G Stock; P Unger
Journal:  J Urol       Date:  1997-11       Impact factor: 7.450

8.  Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases.

Authors:  A P McLaughlin; S L Saltzstein; D L McCullough; R F Gittes
Journal:  J Urol       Date:  1976-01       Impact factor: 7.450

9.  Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases.

Authors:  Friedhelm Wawroschek; Harry Vogt; Hermann Wengenmair; Dorothea Weckermann; Michael Hamm; Mathias Keil; Gerhard Graf; Peter Heidenreich; Rolf Harzmann
Journal:  Urol Int       Date:  2003       Impact factor: 2.089

Review 10.  Lymphatic drainage and CTV in carcinoma of the prostate.

Authors:  Numa Cellini; Stefano Luzi; Giovanna Mantini; Gian Carlo Mattiucci; Alessio G Morganti; Cinzia Digesù; Antonella Bavasso; Francesco Deodato; Daniela Smaniotto; Vincenzo Valentini
Journal:  Rays       Date:  2003 Jul-Sep
View more
  4 in total

1.  Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma.

Authors:  Caroline Rousseau; Thierry Rousseau; Boumédiène Bridji; Amandine Pallardy; Jacques Lacoste; Loïc Campion; Aude Testard; Geneviève Aillet; Ayat Mouaden; Chantal Curtet; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-16       Impact factor: 9.236

Review 2.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

3.  Pre-prostatic tissue removed in robotic assisted lymph node dissection for prostate cancer contains lymph nodes.

Authors:  J Blarer; C Padevit; K Horton; D Pfofe; H John; M Horstmann
Journal:  Urol Ann       Date:  2013-10

4.  Sentinel Lymph Node Biopsy in Prostate Cancer Patients: Results From an Injection Technique Targeting the Index Lesion in the Prostate Gland.

Authors:  Lluís Fumadó; Jose M Abascal; Antoni Mestre-Fusco; Sergi Vidal-Sicart; Guadalupe Aguilar; Nuria Juanpere; Lluís Cecchini
Journal:  Front Med (Lausanne)       Date:  2022-09-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.